Richard Haycock
CEO @ QantX
Kingswear, United Kingdom
Richard Haycock is a seed investor at QantX in Kingswear focused on Health Care and Medical. Richard Haycock is the Co-Founder & CEO QantX.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 22%
Last updated:
For AI agents: llms.txt
Industries Richard Haycock invests in
Stages Richard Haycock invests in
Countries Richard Haycock invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 3 (33%)
- Medical 2 (22%)
- Biotechnology 2 (22%)
- Pharmaceutical 2 (22%)
- Oncology 1 (11%)
Stage
- Seed 3 (33%)
- Pre-Seed 2 (22%)
- Funding Round 1 (11%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Revolver Therapeutics develops peptide therapeutics that target transcription factors to create new routes to cancer treatment. The company uses a proprietary peptide discovery and screening platform, including its Transcription Block Survival technology, to identify functional peptide inhibitors in live cell systems. This platform enables rapidscreening of large peptide libraries and enrichment of molecules that functionally block or modulate transcription factor activity. Revolver Therapeutics focuses on translating its peptide-based transcription factor screening technology into therapeutic candidates for oncology. Its work is based on research spun out from the University of Bath and is aimed at generating next-generation peptide drugs for difficult-to-treat cancers. | $764K / Pre-Seed / Jul 03, 2026 | ||
| iFAST is addressing the Antimicrobial Susceptibility Testing market, reducing the spread of antimicrobial resistance. | $3.9M / Seed / May 27, 2026 | ||
| EnsiliTech is a biopharmaceuticals company that preserves the integrity of vaccines and other biological materials. | $6.1M / Seed / Aug 28, 2025 | ||
| iFAST is addressing the Antimicrobial Susceptibility Testing market, reducing the spread of antimicrobial resistance. | $6.5M / Seed / Nov 04, 2024 | ||
| Developing a new generation of senotherapeutic interventions to target the diseases and aesthetic signs of ageing. | $4.8M / Mar 18, 2024 | ||
| Developing a new generation of senotherapeutic interventions to target the diseases and aesthetic signs of ageing. | $4.7M / Seed / Mar 18, 2024 | ||
| iFAST is addressing the Antimicrobial Susceptibility Testing market, reducing the spread of antimicrobial resistance. | $2.4M / Seed / Feb 16, 2023 | ||
| EnsiliTech is a biopharmaceuticals company that preserves the integrity of vaccines and other biological materials. | $1.1M / Pre-Seed / Jan 17, 2023 | ||
| Developing a new generation of senotherapeutic interventions to target the diseases and aesthetic signs of ageing. | $2.5M / Seed / Jun 09, 2022 |
Co-Investors
About QantX
High impact innovation investment
QantX Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Richard Haycock
CEO
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Richard Haycock invest in?
Richard Haycock invests primarily in Health Care, Medical and Biotechnology startups, most often at Seed and Pre-Seed stage. Most of the 9 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Richard Haycock?
Public channels for Richard Haycock include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Richard Haycock last invest?
The most recent investment recorded for Richard Haycock closed in Jul 2026. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
